ÂÜÀòÂÒÂ×

Falk Saupe has a diverse work history spanning multiple industries. Falk began their career as a student trainee at AJ Roboscreen GmbH in 2002 before moving on to Elbion AG and sanofi-aventis in 2004. In 2007, Falk joined Karolinska Institutet as a Master Thesis Project participant and later conducted research as a PhD candidate at Inserm U1109 from 2007 to 2011. Falk then pursued a postdoctoral position at Inserm U1109 from 2011 to 2012. Falk's research career continued at Uppsala University as a Research Scientist from 2013 to 2016. Falk currently holds the position of Head of In Vivo Pharmacology at T3 Pharmaceuticals AG since July 2021 and has previously served as a Principal Scientist / Project Manager from 2019 to 2021 and a Senior Scientist / Project Manager from 2016 to 2018 at the same organization.

Falk Saupe holds a PhD in Life Sciences from the University of Strasbourg, which they earned from 2007 to 2011. Prior to that, they obtained a Diplôme d'Ingénieur en Biotechnologie (equivalent to a Master of Science) in Molecular Biotechnology from ESBS, where they studied from 2004 to 2007. Falk also holds a Bachelor of Science (B.Sc.) in Molecular Biotechnology from Technische Universität Dresden, which they completed from 2000 to 2003.

In terms of additional certifications, Falk Saupe has obtained a Biosafety Officer Safety Level 2 certification from Curriculum Biosafety b-safe Ltd in March 2022. Falk also holds a Laboratory Animal Science - FELASA Category C certification from the Federation of European Laboratory Animal Science Associations, Uppsala University, which they received in May 2013.